Slide 1: Delivering on Our Commercial Growth Strategy
Delivering on Our Commercial Growth Strategy Corporate Presentation Corporate Presentation August 2023
Slide 2: Disclaimer
Disclaimer These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates. For the purposes of this notice, "pr
Slide 3: Q2 2023 Accomplishments; Shield is an Innovative Specialty Pharmaceutical Company
Q2 2023 Accomplishments Shield is an Innovative Specialty • 50% sequential rise in U.S. Accrufer® prescriptions, to 15,800 Pharmaceutical Company • Substantial acceleration of KPIs: 1st time writers, new ‘Delivering Substantial, Sequential prescriptions, repeat writers U.S. Accrufer® Prescription gr
Slide 4: Isn't it ironic -- The unmet needs of ID/IDA patients are real
The unmet needs of ID/IDA patients are real Up to 70% of people taking Up to 60% of patients will 70% traditional oral iron report 60% discontinue treatment due to gastrointestinal issues1,2 adverse reactions3 Isn’t it ironic -- What is meant to make patients feel better is making them feel worse 1.
Slide 5: Iron Deficiency, with and without anemia (ID/IDA)
Iron Deficiency, with and without anemia (ID/IDA) Untreated ID/IDA is a source of morbidity and mortality ID/IDA is caused by malnutrition, bleeding or problems absorbing iron Current Iron Deficiency Treatment Algorithm Associated with many diseases, especially women's health, inflammatory bowel dis
Slide 6: Accrufer Designed for Efficacy and Tolerability
Accrufer® Designed for Efficacy and Tolerability Accrufer® protects iron within a Proprietary Accrufer® Maltol Formulation and Unique maltol “shield”, enabling it to pass MOA Delivers Elemental Iron to the Small Intestine1, 2 through the stomach This “shield” allows Accrufer® to reach the small inte
Slide 7: Accrufer: Demonstrated Efficacy, Established Safety and Unprecedented Tolerability
Accrufer®: Demonstrated Efficacy, Established Safety and Unprecedented Tolerability Proprietary Accrufer® maltol formulation and unique MOA Data from three Phase 3 studies delivers a total of 60mg1 of elemental iron to the small demonstrated consistent efficacy intestine2 in both the IBD and CKD pop
Slide 8: A Significant Market, Ripe for Innovative Disruption
A Significant Market, Ripe for Innovative Disruption Estimated number of individuals with ~20 MILLION* anemia in the U.S.* Large, defined market: 13.4M prescriptions per year, majority OTC iron Total available US market opportunity of US$2.3B 80% of prescriptions written by Unsatisfied market driven
Slide 9: Our Commercial Partnership Mission
OUR COMMERCIAL PARTNERSHIP MISSION To make Accrufer® the oral iron of choice in the U.S. 9
Slide 10: Exclusive, Multi-Year US Co-Commercial Agreement
Exclusive, Multi-Year US Co-Commercial Agreement Introduction of “Ironic Campaign” refreshes Accrufer® branding May-Jun 2023+ Launch of new sales Shield and Viatris have hit the ground team targets 12,000 top running since May 2023, leveraging strong HCPs & refreshed clinical data, best-in-class dig
Slide 11: Combined Sales Force Dramatically Increases Reach and Efficiency
Combined Sales Force Dramatically Increases Reach and Efficiency Collectively calling on 12,000+ high prescribing HCP’s New Combined Sales Force Launch-savvy team includes 100 sales reps and 12 core leaders, supported by a strong bench of marketing, reimbursement and customer service with experience
Slide 12: 50% Increase in Accrufer Prescription Volume vs. Q1
50% Increase in Accrufer® Prescription Volume vs. Q1 Early Positive Signs following completion of Field Force Expansion +50% Prescriptions by Specialty* 16,000 14,000 9% 12,000 10,000 46% TRx Volume 8,000 45% 6,000 4,000 2,000 Women's Health General Practitioners Other 0 Q3'21 Q4'21 Q1'22 Q2'22 Q3'2
Slide 13: Growth in Prescriptions and Other KPIs Align with Expanded Field Team
Growth in Prescriptions and Other KPI’s align with Expanded Field Team Q2 2023 highlights early impact of expanded commercial team KPIs in Q2 2023 confirm Monthly increases in prescription volume: strong Accrufer® traction: New Prescriptions: +63% Commercial Team +28% +30% Expansion First-Time Write
Slide 14: Introducing the "Ironic Campaign"
Shield and Viatris collaborate to launch new Brand Campaign Introducing the “Ironic Campaign” 14
Slide 15: Disruptive Tactics to Wake Up Dormant Market
Disruptive Tactics to Wake Up Dormant Market Sales Rep Materials Non-Sales Rep Promotion Patient / Social Activation Print tactics New Patient & HCP Website Irony in the Real World Digital enablement Social Media platform/assets 1-833-NO-IRONY Disruptive HCP engagement New focus on national Actively
Slide 16: A sneak peek into the ads
A sneak peak into the ads… HCP Animated Ads* (Programmatic Display) Disruptive Tactics to Wake Up Dormant Market *Indications and usage: ACCRUFeR (ferric maltol) is indicated for the treatment of iron deficiency in adult 16
Slide 17: 100M or ~40% of Eligible Lives Now have Coverage for Accrufer
100M or ~40% of Eligible Lives Now have Coverage for Accrufer® Commercial Plans Robust Patient Access Programs Broad Patient Access programs in place to maximize ability to get patient on Accrufer® at lowest cost ($0 or $25 per month) Payer Contracting Strategy allowed for Prior Authorization for si
Slide 18: High Performance Executive and Commercial Leadership Team
High Performance Executive and Commercial Leadership Team Poised for success, building on experience with over 30 products launches Greg Madison Hans-Peter Rudolf Andy Hurley Todd Hayes Christiana Cioffi Lorraine Nemyier Chief Executive Officer Chief Financial Officer Chief Commercial Officer Head o
Slide 19: Global Partnerships Continue to Progress
Global Partnerships Continue to Progress Deals include upfronts, milestones & double-digit royalties United States EU+ 1 Canada Republic of Korea China + 2 Co-Commercial Sales volume (packs sold) Licence agreement Agreement for single PK Continuing enrolment Agreement, Dec. 2022 increased by 6.5% (2
Slide 20: Full Commercial Deployment Drives Accrufer Adoption
Full Commercial Deployment Drives Accrufer® Adoption Accrufer® market share targeting growth to 4.3% by 2025 4.3% Estimated Annual Prescriptions: Market Share* 2023 125,000 – 160,000 2.9% Market Share* 2024 370,000 – 420,000 1.1% 2025 Market Share* 550,000 – 600,000 2023 [Est.] 2024 [Est.] 2025 [Est
Slide 21: Resources Expected to Support Operations Through Cash Flow Breakeven
Resources Expected to Support Operations Through Cash Flow Breakeven, Expected by YE:2024 Key Financial Highlights Ownership Snapshot Corporate/Institutional Ownership >60%4 Ticker STX Exchange LSE Research Coverage FinnCap Group Mark Brewer Shares Outstanding 713 million Peel Hunt Dr. Miles Dixon A
Slide 22: Upcoming Milestones Highlight Global Commercial Progress
Upcoming Milestones Highlight Global Commercial Progress Accrufer® US Accrufer®/Feraccru® WW Shield Therapeutics 2023: Estimated prescriptions to be H2 2023: KYE Pharma regulatory Sep 2023: Half-Year Financial Results delivered 125,000 – 160,000 approval and launch (Canada) Q4 2023: Trading Update 2
Slide 23: Q2 2023 Accomplishments; Shield is an Innovative Specialty Pharmaceutical Company
Q2 2023 Accomplishments Shield is an Innovative Specialty • 50% sequential rise in U.S. Accrufer® prescriptions, to 15,800 Pharmaceutical Company • Substantial acceleration of KPIs: 1st time writers, new ‘Delivering Substantial, Sequential prescriptions, repeat writers U.S. Accrufer® Prescription gr
Slide 24: Thank You!
Thank You! Greg Madison – Chief Executive Officer Hans-Peter Rudolf – Chief Financial Officer 24